These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 22987660)

  • 1. Adaptive prior variance calibration in the Bayesian continual reassessment method.
    Zhang J; Braun TM; Taylor JM
    Stat Med; 2013 Jun; 32(13):2221-34. PubMed ID: 22987660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Calibration of prior variance in the Bayesian continual reassessment method.
    Lee SM; Cheung YK
    Stat Med; 2011 Jul; 30(17):2081-9. PubMed ID: 21413054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A default method to specify skeletons for Bayesian model averaging continual reassessment method for phase I clinical trials.
    Pan H; Yuan Y
    Stat Med; 2017 Jan; 36(2):266-279. PubMed ID: 26991076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Posterior maximization and averaging for Bayesian working model choice in the continual reassessment method.
    Daimon T; Zohar S; O'Quigley J
    Stat Med; 2011 Jun; 30(13):1563-73. PubMed ID: 21351288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of various continual reassessment method models for dose-escalation phase 1 oncology clinical trials: using real clinical data and simulation studies.
    James GD; Symeonides S; Marshall J; Young J; Clack G
    BMC Cancer; 2021 Jan; 21(1):7. PubMed ID: 33402104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Continual reassessment method for dose escalation clinical trials in oncology: a comparison of prior skeleton approaches using AZD3514 data.
    James GD; Symeonides SN; Marshall J; Young J; Clack G
    BMC Cancer; 2016 Aug; 16(1):703. PubMed ID: 27581751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The continual reassessment method for multiple toxicity grades: a bayesian model selection approach.
    Pan H; Zhu C; Zhang F; Yuan Y; Zhang S; Zhang W; Li C; Wang L; Xia J
    PLoS One; 2014; 9(5):e98147. PubMed ID: 24875783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The continual reassessment method and its applications: a Bayesian methodology for phase I cancer clinical trials.
    Ishizuka N; Ohashi Y
    Stat Med; 2001 Sep 15-30; 20(17-18):2661-81. PubMed ID: 11523075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Critical aspects of the Bayesian approach to phase I cancer trials.
    Neuenschwander B; Branson M; Gsponer T
    Stat Med; 2008 Jun; 27(13):2420-39. PubMed ID: 18344187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Application of the continual reassessment method to a phase I dose-finding trial in Japanese patients: East meets West.
    Morita S
    Stat Med; 2011 Jul; 30(17):2090-7. PubMed ID: 21500239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of phase I dose-finding designs in clinical trials with monotonicity assumption violation.
    Abbas R; Rossoni C; Jaki T; Paoletti X; Mozgunov P
    Clin Trials; 2020 Oct; 17(5):522-534. PubMed ID: 32631095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of model choices for the Continual Reassessment Method in phase I cancer trials.
    Paoletti X; Kramar A
    Stat Med; 2009 Oct; 28(24):3012-28. PubMed ID: 19672839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How to design a dose-finding study using the continual reassessment method.
    Wheeler GM; Mander AP; Bedding A; Brock K; Cornelius V; Grieve AP; Jaki T; Love SB; Odondi L; Weir CJ; Yap C; Bond SJ
    BMC Med Res Methodol; 2019 Jan; 19(1):18. PubMed ID: 30658575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative review of novel model-assisted designs for phase I clinical trials.
    Zhou H; Murray TA; Pan H; Yuan Y
    Stat Med; 2018 Jun; 37(14):2208-2222. PubMed ID: 29682777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Practical model-based dose-finding in phase I clinical trials: methods based on toxicity.
    Thall PF; Lee SJ
    Int J Gynecol Cancer; 2003; 13(3):251-61. PubMed ID: 12801254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Practical modifications to the time-to-event continual reassessment method for phase I cancer trials with fast patient accrual and late-onset toxicities.
    Polley MY
    Stat Med; 2011 Jul; 30(17):2130-43. PubMed ID: 21590790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sample size formulae for the Bayesian continual reassessment method.
    Cheung YK
    Clin Trials; 2013; 10(6):852-61. PubMed ID: 23965547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Using the time-to-event continual reassessment method in the presence of partial orders.
    Wages NA; Conaway MR; O'Quigley J
    Stat Med; 2013 Jan; 32(1):131-41. PubMed ID: 22806898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. np1: a computer program for dose escalation strategies in phase I clinical trials.
    Kramar A; Houédé N; Paoletti X
    Comput Methods Programs Biomed; 2007 Oct; 88(1):8-17. PubMed ID: 17719124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Performance of toxicity probability interval based designs in contrast to the continual reassessment method.
    Horton BJ; Wages NA; Conaway MR
    Stat Med; 2017 Jan; 36(2):291-300. PubMed ID: 27435150
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.